iShares MSCI Europe SRI UCITS ETF EUR (Acc) EUR is a equity ETF from iShares tracking the MSCI Europe SRI index through physical replication. Domiciled in Ireland and launched in 2011, the fund manages about 3.3 bn € and charges a TER of 0.20% — 20 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares MSCI Europe SRI UCITS ETF EUR (Acc) EUR competes with 3 other products on the same index (MSCI Europe SRI): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.20% against a group median of 0.20%. It has been listed since 2011, 15 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 20 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 37.7% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Ireland, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 8.8% |
| Novartis AG | 5.0% |
| Schneider Electric S.E. | 4.4% |
| ABB Ltd | 4.2% |
| Zurich Insurance Group AG | 3.2% |
| LOréal S.A. | 3.0% |
| ING Groep NV | 2.6% |
| AXA SA | 2.2% |
| EssilorLuxottica S. A. | 2.2% |
| Münchener Rück AG | 2.1% |
| Borsa Italiana | IESE | EUR |
| XETRA | IUSK | EUR |
| Francoforte | IUSK | EUR |
| London Stock Exchange | IESG | GBX |
| Euronext Amsterdam | IESE | EUR |
| SIX Swiss Exchange | IESE | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.